bluuebunny/crossref_metadata_2025_split huggingface dataset:
Clinical significance following breast conservation surgery with or without postoperative irradiation in Japanese women with breast cancer.
Authors: Tamaki Kentaro , Tamaki Nobumitsu , Kamada Yoshihiko , Uehara Kanou , Miyashita Minoru , Ishida Takanori , Sasano Hironobu 
Published: March 2020

e11530 Background: Postoperative irradiation or radiotherapy following breast conservation surgery has been reported to be clinically effective in terms of prevention of local breast cancer recurrences. However, it is also true that its local recurrence rate was only 5% to 10%, suggestive of the lack of its clinical benefits in the great majority of the cases. The purpose of this study was to investigate the significance of post-operative radiotherapy in breast conservation surgery by comparing the groups with or without irradiation. Methods: We retrospectively evaluated 1197 Japanese female breast cancer patients (598 irradiation cases and 599 non-irradiation cases). Radiation was administered in a dose of 50 Gy for all conserved breast and additional 10 Gy in those with positive margins or carcinoma within 5mm from surgical margin. We examined the local recurrence rates in those with or without post-operative irradiation according to the status of surgical margin, ER and HER2 in breast cancer tissues. Results: RFS in the irradiated groups were significantly higher than non-irradiated ones in surgical margin positive (P=0.001, HR: 0.334, 95%CI: 0.14-0.79), negative (P=0.015, 0.362, 95%CI: 0.15-0.82), ER positive (P<0.001, HR: 0.249, 95%CI: 0.11-0.54), HER2 negative (P=0.002, HR: 0.316, 95%CI: 0.15-0.65) and non-triple negative patients (P=0.001, HR: 0.382, 95%CI: 0.21-0.69). However, no significant differences were detected between these two groups in ER negative (P=0.288, HR: 0.586, 95%CI: 0.22-1.57), HER2 positive (P=0.969, HR: 0.971, 95%CI: 0.22-4.24) and triple negative (P=0.336, HR: 0.282, 95%CI: 0.02-3.72) patients. Conclusions: Results of our present study could provide clinically inert information as to the selection of the breast cancer patients following conserve surgery.
Feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of breast cancer: An experience from India.
Authors: Somashekar Mohan Kumar , V Murali Subramanian , S Nirmala Srikantaiah , TR Arul Ponni , G Rajeev A , AS Kirthi Koushik , G Janaki M , R Nalini Kilara , S Ramesh Bilimagga 
Published: March 2020

e11536 Background: Majority of the breast cancer patients require adjuvant radiotherapy and chemotherapy for better locoregional and distant control. However the sequencing of these is still debatable . Hence concurrent chemo radiation may avoid the delay in either of the adjuvant therapies. Anthracyclines are not used concurrently with radiation because of severe toxicity. Hence the current study was taken to assess the feasibility of concurrent weekly paclitaxel and radiotherapy in adjuvant treatment of ca breast. Methods: A prospective study was conducted on 22 breast cancer patients, post modified radical mastectomy or breast conservative surgery from November 2008 to April 2010. Chest wall or whole breast radiotherapy was given on Tele Cobalt or Linac for a dose of 50 – 50.4Gy in conventional fractionation. Boost of 16 Gy was given to tumor cavity with photons or electrons for those undergone breast conservative surgery. All patients received Inj.paclitaxel 60 mg/m2 once a week for 5 weeks. After completion of RT, paclitaxel dose was increased to 80mg/m2 for remaining 7 cycles. This was followed by anthracycline based treatment sequentially as per standard adjuvant guidelines. Patients assessed weekly and toxicities graded based on CTC version 03. The minimum follow up was 2 months after completion of chemoradiation. Chi-Square test and Fisher exact test were used to interpret the results with literature. Results: See table below. Skin reaction was more frequent and severe of all toxicities (p=0.003).With available literatures on adjuvant radiation alone the grade III and higher skin reactions are 3% but in our study it is 28% because of which 5/22 (22%) patients had interruption of both chemotherapy and radiation. Conclusions: Concurrent chemoradiation with weekly paclitaxel in adjuvant treatment of ca breast is associated with more skin reactions which may result in significant treatment interruptions. It should be practiced cautiously which requires further randomized control studies to assess the toxicities in detail. [Table: see text]
Demographic variation of Ki67 and its relation with prognosis in triple-negative breast cancer: A single-center pilot project.
Authors: Ahmed Mashrafi , Begum Tahmina 
Published: March 2020

e11539 Background: Ki-67 is a proliferation marker expressed during cell cycle. ASCO does not recommend this biomarker to be done routinely in breast cancer. As triple negative breast cancer lacks all the ASCO recommended biomarkers (estrogen, progesterone and HER-2 gene), non-recommended markers may carry significant prognostic value in different demographic population. Methods: A retrospective chart review was conducted on patients who were diagnosed with triple negative breast cancer at Saint Joseph Hospital, Chicago from 2005 to 2010. We analyzed the data for Ki67 value among age group, race, menstrual status, tumor histology, stage, treatment given and outcome of the treatment. The data was obtained from medical record, cancer registry and department of pathology. Results: Only 35 cases were found retrospectively. The mean age was 55.6 year. Nearly 47% were African American, 38% White and rest was other races. Most of the cases (71%) were post-menopausal. The average follow-up was 214 days with nearly 62% patients remained disease free, 21% suffered from relapse but alive and 18% died from relapse. The analysis of data is presented here in tabulated form. Conclusions: In our study, we could not reach to statistical significance mostly due to small size of the population. Being a rare subtype of breast cancer, a single center data analysis is not sufficient. This pilot study will encourage us to go for a large scale study involving multi-center or cancer registry data of the state of Illinois. [Table: see text] [Table: see text] [Table: see text] [Table: see text] [Table: see text]
Efficacy and safety of weekly oral vinorelbine (NVBO) as single agent in first- or second-line metastatic breast cancer (MBC).
Authors: Morales Serafin , Blancas Isabel , Gonzalvez Maria Luisa , Barnadas Agust , Diaz Nieves , Servitja Sonia , del Barco Sonia , Margeli Mireia , Garcia Carbonero Iciar , Alvarez Ruth , Lopez de Ceballos Maria Helena , Perez Francisco Javier , Llombart Cussac Antonio 
Published: March 2020

e11545 Background: NVBO has shown high activity and good safety profile when given as single agent chemotherapy (CT) for MBC. Oral CT formulations allow maintenance of quality of live and minimal interference with a normal lifestyle. Methods: Main inclusion criteria for this retrospective study were: Histologically or citologically confirmed MBC, no more than 1 prior CT line for MBC; prior (neo)adjuvant CT, hormonetherapy or radiotherapy allowed; adequate bone marrow, kidney and liver function. The study protocol was approved by an ethics committee. Data was collected from patients (p) treated between Apr/2006 and Dec/2010 with NVBO 60 mg/m2 weekly until progression or unacceptable toxicity. 70 patients fulfilled the inclusion criteria. Patient’s characteristics were: Median age, 65 years (range 38-82); >75 years old, 20%; ECOG PS 0-1 in 91% p and PS 2 in 9%; ER+ &/or PR+, 41 p (59%); >2 metastatic sites in 61%; prior (neo)adjuvant CT in 48 p (69%); prior hormonotherapy, 44 p (63%). Measurable disease in 68 p (97%). 1 p received trastuzumab concomitantly. Results: Median number of administrations (a) 11 (range 2-36). 1st/2nd line: 41%/59%. We analyzed 923 a. Dose delayed or reduced due to hematological toxicity in 2.7% a, related non-hematological toxicity in 0.3% a. Dose was reduced in 1% a. Hematological toxicities (%a): neutropenia grade (g) 3, 0.8%; febrile neutropenia 1 p who died due to septic shock after 9 a. Non-hematological toxicities (%a): pain g 3-4, 0.5%; constipation g 3-4, 0.3%; ileus paraliticus g 3, 0.1%; infection g 3, 0.1%; nausea/vomiting g4, 0.1% . 68 p were evaluable for response. 1 CR (1.5%), 19 PR (27.9%) and 16 SD (23.5%) were reported. Objective response (OR) rate 29.4% [CI 95%: 19%-41.7%]. Median progression free survival 4 m [CI 95%, 2.3-5.8]. Median survival has not been reached at the time of analysis. Conclusions: Our findings confirm the consistently produced clinically meaningful efficacy of single agent NVBO for MBC. We observed a favorable safety profile with a particular low incidence of myelosupression and alopecia. We consider that oral vinorelbine is a suitable 1st or 2nd-line treatment for convenient administration in an outpatient environment in selected p with MBC.
Clinicopathologic features of breast cancer in the Texas-Mexico border city of El Paso.
Authors: Nahleh Zeina A. , Zhou Jenny , Ulloa Adolph 
Published: March 2020

e11549 Background: Breast cancer is the leading cause of cancer death in Hispanic women in Texas. El Paso, TX is a large border city of 900,000, 85% Hispanic. Very limited research has been published on this population. Methods: After IRB approval, we analyzed the variables at initial diagnosis of 111 consecutive patients with breast cancer treated at a single academic institution in El Paso, in 2011. Descriptive statistics were utilized. Results: Mean age was 54 years; 101 were Hispanics (91%), 4 White non-Hispanic, 4 African-Americans and 2 Middle Eastern. Six patients (5%) had stage 0, 61 (55%) localized (stages I and II), 32 (29%) loco-regional (stage III), and 12 (11%) stage IV disease. Histology was: 104 ductal (94%), 6 lobular (5%) and 1 neuroendocrine. Sixty two patients (59%) had Estrogen Receptor (ER) positive tumors versus 32 (31%) ER negative. 79 patients (75%) had HER2 negative and 25 (24%) HER2 positive tumors, 1 had unknown HER2. Sixty two (59%) invasive tumors were ER / PR positive/HER2 negative; 11 (10%) were ER/ PR positive/HER2 positive; 14 (13%) ER/PR negative/ HER2 positive; and 17 (16%) Triple negative. 36 patients (32%) were diagnosed at younger than 50 years; 13 (12%) between ages 30 and 40. 16 (45%) of these patients present at advanced or metastatic stages. The Median BMI was 35.5 (range 18-50.4). Treatment was as follows: Mastectomy 44 patients (42%) versus lumpectomy 56 (54%); 84 patients (76%) received chemotherapy and 71 patients (64%) received hormonal therapy. 14 patients (13 %) had cancer recurrences at median of 5.5 years. Conclusions: Consistent with other studies, Hispanic breast cancer patients in El Paso are diagnosed at a younger age , more advanced stages and have a higher prevalence of ER negative and HER2 positive tumors, compared to non-Hispanic historical controls. In addition, our patients had a higher prevalence of metastatic stage IV at diagnosis 11% compared to 6% statewide. Breast cancers among Hispanic women may comprise a distinct biologic spectrum of tumors. Also, more focused research looking at the geographical and socioeconomic differences should be conducted. Dietary and lifestyle habits should also be investigated. Increasing awareness particularly among young Hispanic women is needed.
Results of the East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer (NCT00542191).
Authors: Tiley Stephen , Raab Rachel Elizabeth , Bellin Lisa Sheri , Wong Jan H. , Unger Jackie , Walker Paul R. 
Published: March 2020

e11550 Background: Triple negative (ER negative, PR negative and HER 2 negative) breast cancers (TNBC) lack effective targeted therapy. We sought to determine the benefit of metronomic neoadjuvant chemotherapy utilizing doxorubicin with cyclophosphamide followed by paclitaxel with carboplatin in women with TNBC. Methods: Patients (pts) with TNBC>2cm were eligible (including locally advanced or inflammatory breast cancer). Pretreatment sentinel node biopsy (SLNB) was performed in patients with clinically N0 disease. Treatment consisted of weekly doxorubicin 24 mg/m2 + daily oral cyclophosphamide 60 mg/m2 x 12 weeks followed by weekly paclitaxel 80 mg/m2 + weekly carboplatin AUC 2 x 12 weeks. Granulocyte colony stimulating factor was added for ANC<= 1000. Pts received standard surgery and radiation therapy as indicated. The primary endpoint was pathologic response. Results: Between 2006 and 2011, 17 pts with infiltrating ductal TNBC were enrolled and 15 were analyzed. Age ranged from 25 to 83 (mean age 45yrs), primary tumor size ranged from 2cm to 7cm (mean 3.5cm). Three pts presented with inflammatory breast cancer, 4 had clinical N1 disease and 2 had clinical N0 disease that did not receive SLNB. Six pts underwent SLNB; 3 were pN0 and 3 were pN positive. Two pts came off study due to prolonged neutopenia. Three pts died during therapy-one of MI, one of PE and one had progressive pulmonary disease. No deaths were therapy related. Ten pts completed therapy. One experienced grade 3 (G3) thrombocytopenia, five patients had G4 neutropenia and one developed G3 neuropathy. Ten pts had a clinical complete response (cCR), four had a clinical partial response (cPR) and one progressed on therapy. The rate of pathologic complete response (pCR) was 46.6% (40% pCR, 6.6% CR with foci of DCIS). One patient had a 0.7cm focus of residual invasive carcinoma. Positive nodes were identified in 13.3%-one patient who progressed on therapy and one who experienced a cPR. Conclusions: Neoadjuvant metronomic chemotherapy with weekly doxorubicin plus daily oral cyclophosamide followed by weekly paclitaxel plus carboplatin revealed high rates of pCR with toxicities limited to marrow suppression.
Predictive factors for achieving a pathologic complete remission (pCR) rate after neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer: Results of a multivariant analysis.
Authors: Boelke Edwin , Matuschek Christiane , Roth Stephan L. , Bojar Hans , Janni Johann Wolfgang , Audretsch Werner , Gerber Peter Arne , Speer Vanessa , Baldus Stephan , Nestle-Kraemling Carolin , Peiper Matthias , Budach Wilfried 
Published: March 2020

e11556 Background: In contrast to neoadjuvant chemotherapy they are no predictive factors to estimate the pathologic complete remission (pCR) rate after preoperative chemotherapy (NRT-CHX) in locally advanced breast cancer (LABC). Methods: 315 LABC patients were included in this trial. They were treated during 1991-1998. The last follow up was in November 2011. Radiotherapy was applied with 50 Gy (5x2 Gy / week) to the breast and the supra-/infraclavicular lymph nodes. 101 patients received a 10 Gy interstitial boost (breast conservation). Chemotherapy (CMF, EC or Mitoxantron was applied in 192 patients prior to radiotherapy and in 113 patients simultaneously. Ten patients had no chemotherapy. Age, tumor grade, nodal status, hormone receptor status, simultaneous vs. sequential CHX and the time period up to surgery were examined in multivariate terms for pCR and overall survival. Results: The pCR rate for NRT-CHX after surgery was 29.2%. In multivariante analysis a longer time interval to surgery increased the probability of a pCR (HR 1,17 [95% CI 1,05-1,31], p<0,01). In term of overall survival, the achievement of a pCR is the strongest predictor for long term survival (HR 0,28 [95% CI 0,19-0,56], p<0,001). Conclusions: A long time interval to surgery (> 2 months) increases the probability of a pCR after NRT-CHX. Like in neoadjuvant CHX the achievement of a pCR is an important prognostic factor for long term survival.
Long-term results of capicitabine application in metastatic breast cancer patients.
Authors: Vladimirova Liubov Yu , Kit Oleg I 
Published: March 2020

e11558 Background: Options available after the failure of anthracyclines and taxanes are very limited in BC patients. The long-term experience of Cap application brought us to analyse long-term results of the treatment in this patients. Methods: pts progressed after anthracyclines and taxanes were recruited in 2000-2010. Key elegibility criteria included measurable or nonmeasurable triple-negative MBC or locally recurrent disease, ECOG ≤2, no brain metastases. Cap was administered 1250 mg/ m² BID 1-14 days q3w. Treatment was continued until progression or unacceptable toxicity. A total of 266 courses were estimated. Endpoints include response rate, OS, PFS and safety. Results: 63 patients aged 30-80 years were recruited. 92% had infiltrative ductal carcinoma, triple negative. Time to disease progression was 2.5 mon.- 16 years(mean- 2.6 years). 22% (14) had one disease site: liver 5, lung 5, bones 3, lymphonodes 1. The rest 78% (49)had ≥2 disease sites: lung 32(50.8%), bones 30(47.6%), liver 33(52.3%), soft tissues 21(33.3%). Mean # of disease sites = 2.06. Overal RR was 63.5%(40) including 4 CR(6.3%), 6PR(9.5%) and 30SD(47.6%). Med OS= 9mo, Med PFS= 5 mo. For detailed survival analysis patients were devided into two groups: 1) with RR (40 pts); 2) without RR (23 pts). Med OS was 13 v 4 months (p=0.00004), Med PFS was 6 v 3months respectively(p=0.00016). 8 pts(12.7%) are alive till the abstract submission. Main hematological toxicity was leucopenia1/2 Gd-28.6%, neutropenia 1/2Gd.-26.3%, anemia 1/2 Gd.-19.9%, thrombocytopenia 1/2Gd.- 3.1% courses. Nonhematological toxicity included nausea 1/2 Gd.- 28.5%, vomiting 1/2Gd.- 12.5% and diarrhea 1/2 -16%, hand-foot syndrome 1/2 Gd.-16.9%, thrombophlebitis-3.8%, myalgia and ossalgia -15%, headache 3 Gd. prevented to continue Cap intake in 1 case(1.57%). No significant long-term toxicity was recorded. Conclusions: Cap has a satisfactory effect as well as controlled toxicity. The favorable long-term PFS and OS allow to use Cap in this heavily pretreated pts.
The new primary chemotherapy with S-1 and docetaxel for advanced breast cancer: A first report of N-1 trial.
Authors: Nakagawa Misako , Morimoto Masami , Takechi Hirokazu , Kawakami Yukikiyo , Tangoku Akira 
Published: March 2020

e11560 Background: We reported the result of the efficacy and toxicity of S-1 combined with docetaxel (S-1+DOC) in ASCO 2011 (abstract No.1075). It showed good objective response rate (ORR) and some cases showed of complete response (CR) before middle of 8 cycles regimen. But this regimen was difficult to keep compliance of per oral S-1 intake. To improve pathological CR (pCR) rate, we planned a new protocol of primary chemotherapy with S-1+DOC (N-1 trial). Methods: Patients with advanced breast cancer (stage II-IV) were treated with i.v. docetaxel (40mg/m2) on day1 and oral S-1 (80mg as FT/m2/day) on day1 to 14 every 3 weeks for 4 cycles. According to the RECIST criteria, patients with CR were underwent operation, partial response were continued more 4cycles of S-1+DOC. Stable disease or progressive disease cases were changed regimen for EC or Trastuzumab and Paclitaxel (HT) according to their HER2 status. Adequate supportive therapy was provided for typical adverse events. Primary endpoint is a pCR rate. Secondary endpoints are ORR, breast conservation rate and safety. Results: Between 2009 and 2011, Forty-two patients were originally entered. After 4 cycles of S-1+DOC, CR was noted in 6 cases, and PR in 20 cases. 8 cases of SD and 1 case of PD were underwent EC, 4 cases of SD were underwent HT. Among 36 patients who had completed the whole regimen, 30.7% achieved pCR. ORR was 79.4% and breast conservation rate was 97.4%. Patients could keep an intake more than 80% dose of S-1 was 87%. Adverse events over grade3 were peripheral sensory neuropathy, nausea, nail change and neutropenia. Grade 3, 4 of neutropenia was noted in 62%. Conclusions: The new primary chemotherapy with S-1 and Docetaxel is expected to exhibit satisfactory efficacy and showed the possibility of shortened the term of primary chemotherapy. In order to establish this treatment, it is important to proper response assessment.
Immunogenicity of NY-ESO-1 cancer testis antigen in triple-negative breast cancer.
Authors: Ademuyiwa Foluso Olabisi , Bshara Wiam , Attwood Kristopher , Edge Stephen B , Ambrosone Christine B. , Morrison Carl D , Ritter Gerd , Miliotto Anthony , Gnjatic Sacha , Odunsi Kunle 
Published: March 2020

e11563 Background: NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple negative breast cancer (TNBC) by determining the frequency of expression by immunohistochemistry (IHC) and the degree of inherent immunogenicity to NY-ESO-1. Methods: 168 TNBC and 47 ER+/HER2- primary breast cancer specimens were used to determine NY-ESO-1 frequency by IHC. As previous studies have shown that patients with a robust innate humoral immune response to CT antigens are more likely to develop CD8 T-cell responses to NY-ESO-1 peptides, we evaluated the degree to which patients with NY-ESO-1 expression had inherent immunogenicity by measuring antibodies. The relationship between NY-ESO-1 expression and CD8+ T lymphocytes was also examined. Results: The frequency of NY-ESO-1 expression in the TNBC cohort was 16% versus 2% in ER+/HER2- patients. A higher NY-ESO-1 score was associated with a younger age at diagnosis in the TNBC patients with NY-ESO-1 expression (p= 0.026). No differences in OS (p=0.278) or PFS (p=0.238) by NY-ESO-1 expression status were detected. Antibody responses to NY-ESO-1 were found in 73% of TNBC patients whose tumors were NY-ESO-1 positive. NY-ESO-1 positive patients had higher CD8 counts than negative patients (p=0.018). Conclusions: NY-ESO-1 is expressed in a substantial subset of TNBC patients and leads to a high humoral immune response in a large proportion of these individuals. Given these observations, patients with TNBC may benefit from targeted therapies directed against NY-ESO-1.
Family history record and hereditary cancer risk perception after the creation of a heredofamilial cancer unit in a Spanish hospital.
Authors: Marquez-Rodas Ivan , Perez Ramirez Sara , Cavanagh Podesta Mercedes , Moya Beatriz , Ruperez Blanco Ana Belen , Lopez-Trabada Ataz Daniel , Custodio Cabello Sara , Orera Clemente Maria , Calvo Felipe A. , Martin Miguel 
Published: March 2020

e12003 Background: A comprehensive family history and consideration of the criteria for hereditary cancer risk are essential for oncology practice, since patients and relatives at risk could benefit from further genetic counseling (GC). The objective of this work is to compare the family history record and the hereditary cancer perception risk according to national cancer institute (NCI) criteria before and after the creation of a heredofamilial cancer unit (HFCU). Methods: We retrospectively analyze the clinical records from new incoming patients of our medical oncology service in two cohorts: Cohort 1, from January 2009 to December 2009 (before HFCU creation); and cohort 2, from May 2010 to August 2010 (first four months after HFCU creation). Family history record (yes/no) and NCI general hereditary cancer criteria (unusually early age; one or more first-degree relatives affected with the same or a related tumor; synchronous, bilateral or metachronous cancer in the same individual; atypical presentations; suggestive pathology report) were collected. Results were compared using chi-square test. p <0.05 was considered significant. Results: The table summarizes the results. In cohort 1, 28% (175/621) of clinical records contained the family history, while in cohort 2 this percentage increased to 54% (92/171), (p<0.001). 17% (106/621) patients in cohort 1 and 23% (40/171) in cohort 2, met NCI risk criteria (N.S.) In cohort 1, 13% (14/106) of these patients were referred to GC, while in cohort 2 this percentage increased to 38% (15/40) (p<0.01). Conclusions: The creation of a multidisciplinary HFCU significantly increased the quality of family history records and the referral of patients at risk to GC. However, the percentages still remain limited and further efforts must be made in order to remark the importance of family history in oncology. [Table: see text]